Onartuzumab is a humanized monoclonal antibody designed for the treatment of advanced non-small-cell lung cancer. Onartuzumab was developed by

Genentech Genentech, Inc., is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within ...

, Inc. It is undergoing clinical trials.

References

Monoclonal antibodies {{antineoplastic-drug-stub